Trial Search Results

Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

This randomized phase 3 trial studies how well modified Dakin's solution works in reducing radiation-induced dermatitis, a common skin reaction to radiation therapy, in patients with head and neck cancer undergoing radiation therapy. Modified Dakin's solution may reduce inflammation in the body, which may prevent or reduce dermatitis after radiation therapy.

Radiation therapy in this study is regulatory medical care based on the patient's needs and the radiation oncologist's judgment. It is not possible nor necessary to explicitly define the dose or duration of treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: National Cancer Institute (NCI)

Intervention(s):

  • Drug: Dakin's solution
  • Other: Placebo

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Head and neck cancer who plan to undergo radiation therapy to the head and neck region

   - At least 18 years of age

   - Able to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

   - Prior radiation therapy to the head and neck region or prior chemotherapy for head and
   neck cancer (induction chemotherapy NOT excluded)

   - The physician-approved radiation treatment plan indicates a maximum prescription dose
   of less than 45 Gy

   - Scleroderma or discoid lupus

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061